JP2025517106A - Ｐａｒｐ１阻害剤としての化合物 - Google Patents
Ｐａｒｐ１阻害剤としての化合物 Download PDFInfo
- Publication number
- JP2025517106A JP2025517106A JP2024563976A JP2024563976A JP2025517106A JP 2025517106 A JP2025517106 A JP 2025517106A JP 2024563976 A JP2024563976 A JP 2024563976A JP 2024563976 A JP2024563976 A JP 2024563976A JP 2025517106 A JP2025517106 A JP 2025517106A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- alkyl
- cancer
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2022/089986 | 2022-04-28 | ||
| CN2022089986 | 2022-04-28 | ||
| PCT/CN2023/077272 WO2023207283A1 (en) | 2022-04-28 | 2023-02-20 | Compounds as parp1 inhibitiors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025517106A true JP2025517106A (ja) | 2025-06-03 |
| JP2025517106A5 JP2025517106A5 (enExample) | 2026-02-27 |
Family
ID=88517229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024563976A Pending JP2025517106A (ja) | 2022-04-28 | 2023-02-20 | Ｐａｒｐ１阻害剤としての化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250289814A1 (enExample) |
| EP (1) | EP4514795A4 (enExample) |
| JP (1) | JP2025517106A (enExample) |
| KR (1) | KR20250033148A (enExample) |
| CN (1) | CN119487027A (enExample) |
| WO (1) | WO2023207283A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120081844A (zh) | 2022-01-21 | 2025-06-03 | 新特拉有限公司 | Parp1抑制剂及其用途 |
| AU2023235233A1 (en) | 2022-03-14 | 2024-09-12 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| AU2023259236B2 (en) | 2022-04-28 | 2025-01-09 | Xinthera, Inc. | Tricyclic parp1 inhibitors and uses thereof |
| CN118119629A (zh) * | 2022-09-30 | 2024-05-31 | 中国医药研究开发中心有限公司 | 含氮杂环类化合物及其医药用途 |
| US20250129051A1 (en) * | 2023-10-23 | 2025-04-24 | Gilead Sciences, Inc. | Parp1 inhibitors and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20000016151A (ko) * | 1996-05-29 | 2000-03-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 벤족사지논 도파민 d4 수용체 길항제 |
| GB0227240D0 (en) * | 2002-11-21 | 2002-12-31 | Glaxo Group Ltd | Compounds |
| KR20070027584A (ko) * | 2004-06-17 | 2007-03-09 | 와이어쓰 | 고나도트로핀 방출 호르몬 수용체 길항제 |
| US8404713B2 (en) * | 2007-10-26 | 2013-03-26 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP inhibitors |
| UY31603A1 (es) * | 2008-01-23 | 2009-08-31 | Derivados de ftalazinona | |
| WO2010111626A2 (en) * | 2009-03-27 | 2010-09-30 | Takeda Pharmaceutical Company Limited | Poly (adp-ribose) polymerase (parp) inhibitors |
| SI3999506T1 (sl) * | 2019-07-19 | 2025-06-30 | Astrazeneca Ab | Zaviralci PARP1 |
| US11591331B2 (en) * | 2021-04-19 | 2023-02-28 | Xinthera, Inc. | PARP1 inhibitors and uses thereof |
| WO2022228387A1 (en) * | 2021-04-26 | 2022-11-03 | Fochon Biosciences, Ltd. | Compounds as parp inhibitors |
| KR102867210B1 (ko) * | 2021-10-01 | 2025-10-14 | 신테라, 인크. | 아제티딘 및 피롤리딘 parp1 저해제, 및 이의 용도 |
| CN118119629A (zh) * | 2022-09-30 | 2024-05-31 | 中国医药研究开发中心有限公司 | 含氮杂环类化合物及其医药用途 |
-
2023
- 2023-02-20 CN CN202380050136.0A patent/CN119487027A/zh active Pending
- 2023-02-20 WO PCT/CN2023/077272 patent/WO2023207283A1/en not_active Ceased
- 2023-02-20 EP EP23794719.7A patent/EP4514795A4/en active Pending
- 2023-02-20 US US18/861,016 patent/US20250289814A1/en active Pending
- 2023-02-20 JP JP2024563976A patent/JP2025517106A/ja active Pending
- 2023-02-20 KR KR1020247039613A patent/KR20250033148A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4514795A1 (en) | 2025-03-05 |
| US20250289814A1 (en) | 2025-09-18 |
| KR20250033148A (ko) | 2025-03-07 |
| EP4514795A4 (en) | 2025-12-31 |
| WO2023207283A1 (en) | 2023-11-02 |
| CN119487027A (zh) | 2025-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11591331B2 (en) | PARP1 inhibitors and uses thereof | |
| JP2025517106A (ja) | Ｐａｒｐ１阻害剤としての化合物 | |
| JP7680619B2 (ja) | Ｐａｒｐ１阻害薬及びその使用 | |
| KR102903399B1 (ko) | 트리시클릭 parp1 저해제 및 이의 용도 | |
| RU2686323C2 (ru) | Новые соединения и композиции для ингибирования fasn | |
| KR20200011965A (ko) | Map4k1의 신규한 억제제 | |
| JP6646044B2 (ja) | キナーゼ阻害剤としての化合物および組成物 | |
| US20260098024A1 (en) | Parp1 inhibitors and uses thereof | |
| CN105722840A (zh) | 作为PI3K、mTOR抑制剂的稠合喹啉化合物 | |
| TW202341987A (zh) | 一種Polθ抑制劑 | |
| CA3179671A1 (en) | Kinase inhibitors and uses thereof | |
| CN110078730B (zh) | 作为pi3k/mtor抑制剂的喹啉取代的稠合喹啉化合物 | |
| EP4562002A1 (en) | Substituted bicyclic heteroaryl sulfonamide derivatives for the treatment of cancer | |
| JP2024527565A (ja) | Ｍａｐ４ｋ１阻害物質として使用するためのピリミジン化合物 | |
| HK40111575B (en) | Tricyclic parp1 inhibitors and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260218 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260218 |